^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Mantle Cell Lymphoma
    Drug:Breyanzi (lisocabtagene maraleucel) (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Title:

    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - B-Cell Lymphomas

    Published date:
    04/30/2024
    Excerpt:
    Mantle Cell Lymphoma...CAR T-cell therapy...Lisocabtagene maraleucel (CD19-directed)